quinazolines has been researched along with abt-199 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bojarczuk, K; Chapuy, B; Chen, L; Lawton, LN; Letai, A; Mandato, E; Ryan, JA; Shipp, MA; Stachura, J; Villalobos-Ortiz, M; Wienand, K | 1 |
| Arribas, AJ; Berthold, M; Bertoni, F; Cascione, L; Gaudio, E; Gritti, G; Jourdan, T; Kwee, I; Lange, M; Liu, N; Margheriti, F; Politz, O; Rinaldi, A; Rossi, D; Scalise, L; Sperl, C; Spriano, F; Stathis, A; Sturz, A; Tarantelli, C; Zucca, E | 1 |
2 other study(ies) available for quinazolines and abt-199
| Article | Year |
|---|---|
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2020 |